Vertex Pharmaceuticals (VRTX) on Tuesday announced that the European Commission has granted approval for Alyftrek for the ...

VRTX slips 9% in three months on slow new drug uptake and pipeline hiccups, but CF strength and 2025 growth offer a reason to ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

The IA showed clinically meaningful, disease-modifying benefits for TRIKAFTA ® /KAFTRIO ®, including a 76% and 70% reduction in the cumulative annual rate of pulmonary exacerbations in the U.S ...

Through the first half of the year, Vertex reported profits of $1.6 billion, with 89% of its revenue coming from Trikafta (marketed as Kaftrio in Europe).

Strong demand for its triple-combination cystic fibrosis therapy, Trikafta/Kaftrio, delivered $2.45 billion in revenue. Management slightly raised its 2024 revenue guidance by about 1% at the ...

Trikafta/Kaftrio The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are ...

Trikafta/Kaftrio accounted for about 92% of total sales during the quarter. We forecast about $9.85 billion in revenue for 2023, representing growth of 10% over 2022.

However, higher Trikafta/Kaftrio sales are likely to have caused sales erosion of Vertex’s other CF drugs. While CF remains the main area of focus, the company saw rapid success in its non-CF ...

Vertex currently markets four cystic fibrosis (CF) products — Trikafta/Kaftrio, Symdeko (marketed as Symkevi in Europe), Orkambi and Kalydeco. ...